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146Objectives: To identify pretransplant factors associated with postprocedural right ventricular failure and the
relationship between right ventricular failure and long-term survival in children.
Methods: Records were reviewed for children having heart transplantation from 2000 to 2006.
Results: Right ventricular failure was identified by clinical and echocardiographic parameters in 33/129 (25%)
recipients: dilated cardiomyopathy in 14/90 (15%), congenital heart disease in 11/27 (41%), and restrictive
cardiomyopathy in 8/12 (66%). In 9 of 12 (75%), known elevated (reactive) pulmonary vascular resistance
progressed to right ventricular failure. In a further 23/117 (20%) recipients, pulmonary vascular resistance within
predefined acceptable range progressed to right ventricular failure. Multiple logistic regression analyses indicated
elevated pulmonary vascular resistance (odds ratio 12.30; 95% confidence interval 2.73, 55.32; P ¼ .001) and
primary diagnosis, restrictive cardiomyopathy (odds ratio 9.21; 95% confidence interval 2.07, 41.12;
P ¼ .004), and congenital heart disease (odds ratio 4.07; 95% confidence interval 1.36, 12.19; P ¼ .012)
were strongly associated with right ventricular failure, but duration of heart failure, pretransplant mechanical sup-
port, donor status, and ischemic times were not. Treatment included inhaled nitric oxide in 28 (84%), mechanical
support in 10 (31%), hemofiltration in 13 (40%), and retransplantation in 2. A Cox multiple regression model
including: primary diagnosis, right ventricular failure, and elevated pulmonary vascular resistance indicated
that only the latter was independently linked with eventual mortality (hazards ratio 5.45; 95% confidence interval
1.36, 21.96; P ¼ .017).
Conclusions: Primary diagnosis and pretransplant elevated reactive pulmonary vascular resistance are both
linked to the evolution of right ventricular failure. Pulmonary vascular resistance assessment in end-stage heart
failure is challenging; therefore, avoidance of right ventricular failure may not always be possible. Aggressive
early treatment may mitigate the effects of right ventricular failure: pretransplant elevated pulmonary vascular
resistance was independently associated with long-term survival, but right ventricular failure was not. (J Thorac
Cardiovasc Surg 2010;139:146-53.)Early transplant literature has suggested that preoperative
pulmonary hypertension with increased pulmonary vascular
resistance (PVR) is a risk factor not only for early death1-4
but also for perioperative morbidity such as posttransplant
infections and arrhythmias.5 Recently, significant advances
have been made in pediatric heart transplantation with
much improved overall outcomes,6-9 but recipient selection
remains a key factor in determining successful outcome.
Despite advances in perioperative management and careful
preselection, right ventricular failure (RVF) still occurs in
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The Journal of Thoracic and Cardiovascular SurgRVF in the current era of pediatric transplantation are not
well described. Registry data from the International Society
of Heart and Lung Transplantation reveal that RVF accounts
for 50% of all cardiac complications and 19% of early
deaths in adult patients in the posttransplant period.13 As
in adults, threshold hemodynamic values to predict RVF
are not entirely reliable in children.1 Long-standing end-
stage heart disease, regardless of etiology, can cause
progressively increasing pulmonary venous hyperten-
sion.14,15 Raised PVR is frequently documented in patients
with long-standing restrictive cardiomyopathy (RCM)16-18
as well as in patients with failing single-ventricle pallia-
tion,19 and increasing numbers of patients with palliated
single ventricle are being listed for transplantation.20,21 In
addition, preoperative assessment of PVR by cardiac cathe-
terization may not always yield adequate or reliable informa-
tion, especially when hemodynamically tested in a low
cardiac output state.19,22 It is also speculated that prolonged
graft ischemic times with suboptimal right heart protection
may potentially be associated with RVF in the immediate
postoperative period.ery c January 2010
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BSA ¼ body surface area
CHD ¼ congenital heart disease
DCM ¼ dilated cardiomyopathy
ECMO ¼ extracorporeal membrane oxygenation
iNO ¼ inhaled nitric oxide
PVR ¼ pulmonary vascular resistance
PVRI ¼ pulmonary vascular resistance index
RCM ¼ restrictive cardiomyopathy
RVF ¼ right ventricular failure
TPG ¼ transpulmonary gradientT
XWe performed a single-center, retrospective analysis of all
patients with orthotopic heart transplantation over a period
of 7 years and identified those with acute RVF in the imme-
diate postoperative period. In particular, we aimed to iden-
tify factors linked with the evolution of RVF and to study
the subsequent relationship between RVF and long-term
outcome.
METHODS
The study was registered with and approved by the Research and Devel-
opment Office at the Institute of Child Health, London. All heart transplant
recipients within the study time frame were included, and a subgroup with
acute RVFwas identified. The diagnosis of RVFwas a ‘‘clinical syndrome’’
based on a constellation of clinical ‘‘bedside’’ and echocardiographic signs.
These were: elevated central venous pressure and raised pulmonary artery
pressures more than two-thirds systemic arterial pressure on invasive mon-
itoring; clinical picture of a low cardiac output state; and supportive
echocardiographic features including poor systolic function of the right
ventricle with significant tricuspid regurgitation and raised estimated right
ventricle systolic pressure in the context of preserved left ventricular ejec-
tion. The pulmonary artery pressures were not used in isolation, as a failing
right ventricle may not be able to generate higher pressures. Patients with
acute graft failure with predominant left ventricular failure or biventricular
failure were excluded from the definition of RVF.
The following data were collected.
1. Preoperative variables: primary cardiac diagnoses of (a) dilated cardio-
myopathy (DCM), (b) RCM, and (c) congenital heart disease (CHD); du-
ration of end-stage heart failure from diagnosis to transplantation;
presence of increased PVR (defined below); age; weight and requirement
for pretransplant ventilation and/or mechanical support.
2. Intraoperative variables: graft ischemic time, donor/recipient age weight
and body surface area (BSA) mismatch, donor cause of death, and mar-
ginal donor status (defined below).
3. Postoperative status: duration of ventilation, use of inhaled nitric oxide
(iNO), right ventricular assist device, and extracorporeal membrane ox-
ygenation (ECMO), length of intensive care stay, and subsequent sur-
vival status up to the end of January 2008.Pretransplant PVR
Acceptable institutional listing criteria for heart transplant for
preoperative PVR were defined as PVR index (PVRI) 6 WU $ m2 and/
or a transpulmonary gradient (TPG) 15 mm Hg and mean pulmonary
artery pressure<25 mm Hg. The catheter data were reviewed to assess re-
versibility of PVR in different situations with 1.0 FIO2 and iNO. Echocardio-The Journal of Thoracic and Cagraphic parameters in the absence of catheter data for identification of
preoperative PVR were defined (as per convention) primarily on the basis
of raised (two-thirds of systemic systolic pressure and above) estimated
right ventricular systolic pressure (RVSP) calculated from the tricuspid
regurgitant jet peak systolic gradient and other supporting data specific to
the underlying diagnosis. A group with elevated PVR was then identified
from patients who had pulmonary hemodynamic data outside these defined
acceptable values but in all, there was evidence of pulmonary vascular
reactivity on hemodynamic testing.
Marginal Donor Status
Marginal donor statues was defined in our institution as follows: donor
age>40 years, size mismatch of>3 times weight, high inotropic need,
cardiac arrest in the donor, and a history of donor smoking or drug abuse.
Data Analysis
Comparison between the 2 groups (patients with and without RVF) was
performed using Wilcoxon rank sum test for continuous and a chi-square
test for categorical variables. Continuous variables are expressed as median
with interquartile range (IQR). Univariate logistic regression analysis was
performed to assess the relationship between variables of interest and
RVF. Risk factors that appeared statistically related to the occurrence of
RVF were further investigated using multiple logistic regression models.
Long-term outcome of recipients was evaluated with a Cox proportional
hazards model, considering the importance of potential risk factors for death
over time. Again, factors that appeared to be statistically related to outcome
on univariate analysis were further investigated using a Cox multiple
regression models.RESULTS
Over this 7-year period, a total of 129 children had
orthotopic heart transplantation. The primary diagnosis
was DCM in 90 (70%), CHD in 27 (21%), and RCM in
12 (9%). The median age at transplantation was 9.5 (IQR
2.8, 13.6) years.Patients With Acute RVF
Of 129 recipients, acute posttransplant RVF developed in
33/129 (25%) as identified by clinical, hemodynamic, and
echocardiographic parameters. In 14 of 33, RVF was identi-
fied immediately after coming off bypass; RVF developed in
a further 15 within 24 hours; and in the remaining 4, between
24 and 48 hours. The median highest central venous pressure
in those with RVF was 20 (IQR 16, 22), and the median left
atrial pressure was 10 (IQR 8, 11).Comparison With the Non-RVF Group
Primary diagnosis. RVF was significantly linked to the
primary diagnosis (P< .001) and was most prevalent in
RCM 8/12 (66%), then CHD 11/27 (41%), and least com-
mon in DCM 14/90 (15%; Table 1). Of the 11 RVF patients
with CHD, 7 (64%) were transplanted following functional
single-ventricle palliation (3 after bidirectional cavopulmo-
nary anastomosis, 3 after total cavopulmonary anastomosis,
1 after Kawashima surgery), and 4 were transplanted follow-
ing biventricular repair. There was no difference in therdiovascular Surgery c Volume 139, Number 1 147
TABLE 1. Patient characteristics: Diagnosis, preoperative and
operative variables in those with and without RVF
Characteristics
RVF
(n ¼ 33)
No RVF
(n ¼ 96)
P
value
Age (y) 6.7 (2.6, 13.1) 10.8 (2.9, 13.7) .50
Diagnosis <.0001
DCM (n ¼ 90) 14 (15%) 76 (85%)
RCM (n ¼ 12) 8 (66%) 4 (33%)
CHD (n ¼ 27) 11 (41%) 16 (59%)
Duration of heart failure (d) 420 (147, 571) 169 (83, 375) .03
Elevated PVR 9 (27%) 3 (3%) <.001
Ischemic time (min) 236 (200, 280) 223 (190, 254) .21
Donor to recipient age ratio 2.17 (1.30, 2.50) 1.75 (1.20, 2.90) .47
Donor to recipient weight ratio 1.7 (1.4, 2.3) 1.6 (1.2, 2.0) .77
Donor to recipient BSA ratio 1.48 (1.24, 1.71) 1.33 (1.11, 1.62) .07
Marginal donor 11 (33%) 40 (41%) .40
Pretransplant mechanical
support
7 (21%) 20 (21%) .96
Days ventilated 11.2 (3.7, 18) 3.3 (1.2, 11.6) .003
Days in intensive care 12.8 (7.0, 22) 6.6 (3.2, 16) .006
Results are median (interquartile range) or n (%). All medians compared with Wil-
coxon rank sum test and proportions by chi-square test. BSA, Body surface area;
CHD, congenital heart disease; DCM, dilated cardiomyopathy; PVR, pulmonary
vascular resistance; RCM, restrictive cardiomyopathy; RVF, right ventricular failure.
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palliation between the 2 groups.
Duration of heart failure from diagnosis to transplanta-
tion. The median duration of end-stage heart failure from
diagnosis to transplantation in the RVF group was signifi-
cantly longer at 420 (IQR 147, 571) days, compared with
the non-RVF group: 169 (IQR 83, 375) days (P ¼ .03).
Pretransplant PVR. Themajority of patients with elevated
PVR 9/12 (75%) developed RVF (P<.001); the PVR group
is described below. However, 24/33 (72%) children with
RVF did not have recognized signs of raised PVR, as mea-
sured by echocardiography in 14 (median calculated RVSP
36 mm Hg; IQR 36, 40) and by cardiac catheterization in 10
(median TPG 8 mm Hg; IQR 8, 9). Of the 14 who did not
have catheter examination, 10 had DCM, 4 had CHD, and
5 were bridged on ECMO to transplant. All had severe
end-stage heart failure with median left ventricular shorten-
ing fraction of 10% (IQR 9, 14).
Pretransplant mechanical support. Of all included
patients, 27/129 (21%) were bridged to transplant on
mechanical support; this proportion was similar between
the RVF and non-RVF groups (P ¼ .96).
Intraoperative variables. The median graft ischemic time
was 236 (IQR 200, 280) minutes in those with RVF, and this
was not statistically different in the non-RVF group
(P ¼ .95). There was no significant difference in either the
donor to recipient weight ratio (P ¼ .77) or the donor to
recipient age ratio (P ¼ .47). There was some suggestion
that an increased donor to recipient BSA ratio may have
been linked to RVF (P ¼ .07), but this was not statistically
significant. Based on our institutional criteria, there was no148 The Journal of Thoracic and Cardiovascular Surgevidence that the percentage receiving a marginal donor
organ differed between the RVF and non-RVF groups
(P ¼ .40). The 3 major causes of donor death were trauma
in 53 (41%), intracranial hemorrhage in 43 (33%), and hyp-
oxia in 11 (9%), of which 2 were due to smoke inhalation;
there was no statistical relationship between donor cause
of death and RVF (P ¼ .16).
The Elevated PVR Group
Pretransplant PVR was diagnosed on the basis of catheter
data for those with RCM, on the basis of echocardiographic
data in those with DCM except in 7 (for whom catheter data
were available), and on the basis of echocardiographic and
catheter data for the CHD group. A small group of 12/129
(9%) patients had elevated pretransplant PVR. The median
TPG in those who were catheterized (n¼ 9) was 16 (IQR 15,
19), mean pulmonary artery pressure was 40 (IQR 38, 42),
and the estimated median RVSP in those who did not have
cardiac catheterization was 64 (IQR 64, 66) mm Hg. Four
(3 with RCM and 1 with DCM) had preoperative vasodilator
treatment with prostacyclin with some reduction in
either TPG or PVRI. All had some reversibility of PVR
and were considered acceptable for listing for heart
transplantation with the option of right ventricular assist
device to be initiated in the operating room in the event of
deterioration. There were 3 patients in whom, despite
concerns for borderline elevated PVR, there was no clinical
syndrome of acute RVF, though all had prolonged intensive
care stay. We found no evidence that children with elevated
PVR were given better-matched organs than those recipients
who did not have PVR concerns in terms of either weight
(P ¼ .83), BSA (P ¼ .84), or age (P ¼ .90).
The RCM Group
The RCM group was particularly at risk of RVF. All 8
patients with RCM that developed into RVF had preopera-
tive cardiac catheter: median TPG was 15 (IQR 12, 17)
and PVRI was 4.7 (IQR 4.4, 5.0).
Regression Models: Variables of Interest and RVF
Multiple logistic regression analyses indicated that
elevated PVR (odds ratio [OR] 12.30, 95% confidence inter-
val [CI] 2.73, 55.32; P ¼ .001), primary diagnosis (RCM:
OR 9.21, 95% CI 2.07, 41.12; P ¼ .004), and CHD (OR
4.07, 95% CI 1.36, 12.19; P ¼ .012) were independently
associated with RVF (Table 2). The duration of heart failure,
linked to RVF on univariate analysis, became nonsignificant
with P ¼ .65.
Postoperative Management of RVF
All patients with RVF received conventional ventilation
with alkalinization and avoidance of respiratory acidosis,
a phosphodiesterase inhibitor (milrinone) infusion, and
inotropic support (Table 3). iNO was started in 28ery c January 2010
TABLE 2. Univariate and multiple logistic regression analyses of risk
factors for RVF
Univariate Multiple
Factor
Odds
ratio
95%
CI
P
value
Odds
ratio
95%
CI
P
value
Heart failure
(per 6 mo)
1.49 1.08, 2.06 .015 1.10 0.74, 1.65 .65
Pretransplant
ventilation
0.49 0.20, 1.20 .12 N/A
Pretransplant ECLS 1.02 0.39, 2.69 .96 N/A
RCM vs DCM 10.86 2.88, 41.00 <.001 9.21 2.07, 41.12 .004
CHD vs DCM 3.73 1.45, 9.71 .007 4.07 1.36, 12.19 .012
Pretransplant
elevated PVR
11.62 2.92, 46.27 .001 12.30 2.73, 55.32 .001
Total ischemic time
(per hour)
1.21 0.82, 1.79 .32 N/A
CHD, Congenital heart disease; CI, confidence interval; DCM, dilated cardiomyopa-
thy; ECLS, extracorporeal life support; PVR, pulmonary vascular resistance; RCM,
restrictive cardiomyopathy; RVF, right ventricular failure.
TABLE 3. Overview of treatment for RVF in the 3 primary diagnostic
categories
Treatment
of RVF DCM (n ¼ 14) RCM (n ¼ 8) CHD (n ¼ 11)
Inhaled nitric
oxide
12/14 (85%) 6/8 (75%) 10/11 (90%)
Prostacyclin 2/14 (14%) 7/8 (87.5%) 4/11 (36%)
Mechanical
support
3/14 (21%) 4/8 (50%) 3/11 (27%)
3 ECMO 1 ECMO, 1 RVAD,
2 RVAD/ECMO
2 ECMO,
1 RVAD
Hemofiltration 3/14 (21%) 5/8 (62.5%) 5/11 (45%)
Atrial septostomy 0 1/8 (12.5%) 0
Retransplantation 0 1/8 (12.5%) 1/11 (9%)
Days ventilated 8.2
(3.8, 19.5)
15.7
(7.0, 51.3)
6.6
(3.9, 14.1)
Days in intensive
care
9.3
(6.3, 20.8)
17.6
(11.6, 42.3)
12.8
(6.9, 17.4)
Survival to
hospital discharge
14/14 (100%) 6/8 (75%) 9/11 (82%)
CHD, Congenital heart disease; DCM, dilated cardiomyopathy; ECMO, extracorpo-
real membrane oxygenation; RCM, restrictive cardiomyopathy; RVAD, right
ventricular assist device; RVF, right ventricular failure. Results are median (interquar-
tile range) or n (%).
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hours. In 11 patients, iNO was started in the operating the-
ater when RVF was recognized immediately coming off
bypass. Prostacyclin infusion was started in 13 (40%) at
a median of 3 (IQR 2, 4) days after transplant and contin-
ued for a median duration of 10 (IQR 4, 18) days. Renal
support in the form of continuous venovenous hemofiltra-
tion was required in 13 (40%) of those with RVF. Me-
chanical support was needed in 10 (31%): 6 patients on
ECMO and 4 with right ventricular assist devices (2 con-
verted to ECMO due to pulmonary failure). The trigger
for mechanical support was worsening clinical condition
despite maximizing conventional RVF treatment; 5 were
started on mechanical support in the operating theater
and in 5 (3 on the day of transplant and 2 on day 2
of transplant) cases, mechanical support was initiated in
the cardiac intensive care unit. The median number of
mechanical ventilation days for patients with RVF was
11.2 (IQR 3.7, 18) and the median length of ICU stay
was 12.8 (IQR 7, 22) days. Both parameters were signifi-
cantly elevated in the RVF group (P ¼ .003 and .006,
respectively, shown in Table 1), reflecting the greatly in-
creased morbidity from RVF.
Survival Outcome
Survival outcomes are shown in Table 4 and Figures 1 and
2. Over a median follow-up period of 3.7 (IQR 2.1, 5.3)
years, there were 14 deaths (10.8%). Early postprocedural
survival for the cohort was 122/129 (94.6%), and actuarial
survival at 5 years was 86.1% (95%CI 76.6, 91.9%). Seven
were postprocedural deaths: 4 from RVF and 7 were late
deaths at a median interval of 2.1 (IQR 1.8, 3.5) years
from the transplantation. A univariate Cox model including
478.1 years of patient follow-up time indicated weak evi-
dence that RVF (hazard ratio [HR] 2.66, 95% CI 0.91,The Journal of Thoracic and Ca7.71; P ¼ .07) and RCM (HR 3.46, 95% CI 0.90, 13.24;
P ¼ .07) were associated with greater mortality risk. There
was strong evidence that pretransplant elevated PVR was
a related to mortality (HR 6.37, 95% CI 2.12, 19.05;
P ¼ .001). A Cox multiple regression model including pri-
mary diagnosis, RVF, and elevated PVR indicated that
only PVR was an independent predictor of long-term
outcome (HR 5.45, 95% CI 1.36, 21.97; P ¼ .017), and
both RVF and RCM were nonsignificant (Figures 1 and 2).
DISCUSSION
Our Results Summary
In this single-center retrospective study over a 7-year
period, we found that acute RVF developed in one-fourth
of the carefully selected pediatric heart transplant recipients
in the immediate postoperative period. Surprisingly, the
majority (24/33; 72%) of children with RVF were judged
to have acceptable PVR on pretransplant assessment. As
well as pretransplant elevated PVR, the primary diagnosis
(RCM then CHD) was significantly linked to the evolution
of RVF. This may reflect the difficulties assessing PVR in
certain children with end-stage heart failure. The RVF group
experienced greater early morbidity and required aggressive
intensive care support. Although some early deaths were
attributed to RVF, survival analysis indicated the only
important predictor of long-term outcome was a pretrans-
plant elevation in PVR.
How Do Our Results Compare With Other Studies?
Huang and colleagues12 studied risk factors for primary
graft failure in 165 pediatric transplant recipients overrdiovascular Surgery c Volume 139, Number 1 149
TABLE 4. Univariate and multiple Cox regression analyses of risk
factors for death
Univariate Multiple
Factor
Hazard
ratio
95%
CI
P
value
Hazard
ratio
95%
CI
P
value
RVF 2.66 0.91, 7.71 .07 1.03 0.25, 4.30 .97
Pretransplant ECLS 2.09 0.70, 6.26 .19 N/A
RCM 3.46 0.90, 13.24 .07 2.23 0.51, 9.87 .29
CHD 1.36 0.36, 5.14 .65 1.39 0.36, 5.41 .63
Elevated PVR 6.37 2.12, 19.05 .001 5.45 1.36, 21.97 .017
CHD, Congenital heart disease; CI, confidence interval; ECLS, extracorporeal life
support; PVR, pulmonary vascular resistance; RCM, restrictive cardiomyopathy;
RVF, right ventricular failure.
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FIGURE 1. Kaplan-Meier survival statistics for patients divided by the
presence of right ventricular (RV) failure. The difference between the
2 groups was not statistically significant using Cox regression.
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Xa period of 15 years and reported occurrence of isolated RVF
in 9%. This study identified pretransplant ventilator support
and PVRI as significant risk factors for the development of
RVF. The higher incidence of RVF in our cohort may reflect
differences in case mix—for example, more patients with
RCM or single-ventricle palliation. The use of ECMO for
RVF was greater in the cohort of Huang and colleagues12
than ours, perhaps reflecting the more recent use of iNO
and other conventional modalities in our patients. Fukush-
ima and associates10 studied risk factors for graft failure in
pediatric heart transplantation and found that the mortality
rate from pulmonary hypertension in infants was signifi-
cantly lower than that in older children despite the overall
mortality rate being higher in the infants. This study con-
cluded that older patients experienced greater PVR-related
mortality after heart transplantation, especially patients
with CHDwho received a graft preserved more than 6 hours;
however, long-term follow-up was not described. Bando and
coworkers23 assessed the influence of preoperative factors
on outcome after pediatric heart transplant in 2 different
eras over a 10-year period. This study, like ours, found
that elevated TPG was the only independent risk factor for
death overall, in both early and late postoperative periods.
In a study by Hsu and colleauges24 from the early 1990s,
a pretransplant diagnosis of CHD increased the likelihood
of graft failure, possibly related to the need for longer oper-
ation, higher risk of bleeding, and difficult implantation.0.
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FIGURE 2. Kaplan-Meier survival statistics for patients divided by the
presence of pretransplant elevated pulmonary vascular resistance (PVR).
The difference between the 2 groups was statistically significant using
Cox regression.The Role of Elevated PVR
Elevated PVR is a known risk factor for death following
transplantation,25 and RVF in the context of increased
PVR has been described in earlier series.23,26-28 When
considering a patient with reactive but elevated PVR for
transplantation, the expectation is that resistance will fall
after transplantation. Bhatia and colleagues29 evaluated
posttransplant resolution of pulmonary hypertension and
reported a continual decrease in hemodynamic indices
throughout the first year with 80% of patients demonstrating
normal PVR at 1 year. In a study of patients transplanted
for RCM, Kimberling and associates17 reported that the150 The Journal of Thoracic and Cardiovascular Surgposttransplant PVR had normalized, and similar findings
were reported by Gajarski and coworkers.30
Accurate assessment of PVR prior to transplantation and
the related decision making present particular challenge in
the pediatric heart failure population. There is wide variation
in the acceptance criteria for heart transplant listing with
respect to indices of PVR between different centers, though
several investigators have reported that posttransplant RVF
is unlikely if the PVRI is less than or equal to 4 WU $ m2
with vasodilator therapy17,21,23,30; however, some maintain
that a pretransplant PVRI less than 8 WU $ m2 is accept-
able.31 The reactivity of the pulmonary vascular bed is
considered to be more important than the absolute resistance
in determining suitability.30,32ery c January 2010
Hoskote et al Cardiothoracic Transplantation
T
XVariation in PVR has been described in individual
candidates waiting for heart transplantation, making the in-
terpretation of findings more difficult.33 In the context of
newer pulmonary vasodilators and the use of mechanical
assist devices to decrease PVR, the definition of true, fixed
elevated PVR has become more uncertain.21 Assessment
of PVR in the patient with single-ventricle palliation, those
with complex CHD, and those with long-standing DCM
and either very poor function or mechanical assistance
may be extremely difficult, and at times accurate determina-
tion may be impossible3 and carries significant morbidity
and mortality. In light of this potential risk, our institutional
policy is to perform cardiac catheterization in all patients
with a primary diagnosis of RCM and in those with CHD.
We do not catheterize those with DCM unless there is
disproportionately elevated pulmonary artery pressure.
In our series, all 12/12 with RCM and 25/27 with CHD
had pretransplant catheter data and only 7/90 DCM were
catheterized.
Recent reports on the benefit of sildenafil in peritransplan-
tation phase34 and use of ventricular assist devices35 in
reducing pretransplant elevated PVR need to be supported
with studies on larger numbers of patients. However, there
are major resource implications, and risks of ventricular
assist device support are not inconsequential.
Consideration of Other Factors as Causes of RVF
We considered the potential effects of donor-related
myocardial strain: organ preservation and ischemia-reperfu-
sion injury, cardiopulmonary bypass–induced elevated
PVR, and postoperative pulmonary dysfunction, which
can contribute or result in acute right heart dysfunction.
Prolonged ischemic time especially in combination with
pretransplant elevated PVR has been implicated in RVF in
adult36 though not in pediatric studies.37,38 However, in
our cohort, neither graft ischemic time nor other donor fac-
tors appeared to be related to RVF. The only marginal find-
ing was a borderline suggestion that greater donor to
recipient BSA ratio may have been linked with RVF, but
this finding was not conclusive. We checked whether there
was any evidence for selection of more oversized grafts in
patients deemed to be at risk of RVF in terms of high
PVR, and we found no indication that this was the case.
All donor to recipient weight ratios were within acceptable
range (neither undersized nor oversized, both of which are
implicated in primary graft failure).5,12 There is an intuitive
belief that oversized allografts may support the right
ventricle to generate sufficient pressures and thus compete
with the raised PVR. However, there is no clear evidence
that oversizing is beneficial. On the contrary, there is
evidence that large donors may have a negative impact on
survival in this group of patients from the study published
by Costanzo-Nordin and associates,29 who found that
when percent donor weight–recipient ideal weight mismatchThe Journal of Thoracic and Cawas used as a continuous variable, donor heart oversizing
was negatively related to survival, independent of preopera-
tive TPG values (P< .05).39
We considered the effect of pretransplant mechanical
ventilation and mechanical support, finding neither was asso-
ciated with RVF; this is in contrast to the study by Huang and
colleagues.12 The majority (24/27; 88.9%) of patients who
were bridged to transplant in our cohort had a primary diagno-
sis of DCM, which was the group at lowest risk of RVF. Pro-
longed heart failurewas associatedwith increased risk ofRVF
on univariate analysis, but this was most likely linked to the
more important predictor, elevated PVR, and consequently
became nonsignificant in the multiple regression analyses.
Management of Acute RVF
Vasodilator therapy is required in the management of
acute RVF, and the selectivity of iNO to the pulmonary vas-
culature makes this the ideal agent; this was used in 84% of
our cohort. Comparisons with sodium nitroprusside, prosta-
cyclin, and prostaglandin demonstrated that iNO provided
similar pulmonary vasodilatation to prostacyclin but, impor-
tantly, iNO was the only vasodilator that was selective
following transplantation.40-42 Early use of iNO before ter-
mination of cardiopulmonary bypass has been described
by Ardehali and coworkers43 in 16 adults post–heart trans-
plantation; they found that early iNO use reduced PVR
and improved RV stroke volume and improved survival.43
In a retrospective study of pediatric heart transplant recipi-
ents, Bauer and colleagues44 showed that prophylactic use
of intravenous vasodilator/iNO and phosphodiesterase in-
hibitor, started at weaning of cardiopulmonary bypass and
continued until reduction of PVR and/or adaptation of RV
to an elevated afterload, prevented RVF. A similar preventa-
tive anesthetic and perioperative strategy has been described
by Schindler and colleagues45 in their study of 90 transplants
over a 13-year period. Use of mechanical support for graft
failure12,46 and improved survival are well described. The
survival was 60% in those supported on ECMO in our
cohort, which is similar to other series.12 In subsequent
patients after this series, we have elected to create a small
atrial communication in the donor heart in those felt to be
at greatest risk of RVF. The result of this strategy on
outcome will need to be analyzed over time.
Outcome
The outcome for this pediatric heart transplant cohort is
favorable in comparison with other pediatric series, with
a postprocedural survival rate of 94.6% and an actuarial
5-year survival rate of 86.1%. The role of pretransplant
PVR in determining adverse long-term outcome is well rec-
ognized, and the multiple regression analyses indicated that
this clearly remains of key importance. We have noted that
acute RVF posttransplant is a major source of postoperative
morbidity and that this contributes to early mortality, but therdiovascular Surgery c Volume 139, Number 1 151
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the highest level of PVR. The survival analysis ultimately
indicated that with careful and aggressive postoperative
management, a large proportion of RVF cases responds to
treatment and recover.
We have looked at limited factors relating to RV failure
and acknowledge that many other issues may be implicated
in determining long-term outcome such as compliance,
rejection episodes, and cytomegalovirus infection, to
mention a few, which we have not analyzed. Also, with
the lack of effect of RVF on long-term outcome, there is
the possibility of type II error. However, we found that reac-
tive pretransplant PVR, though it can be manipulated and
may decrease with time posttransplant, nevertheless still
remains significant enough to have an impact on long-term
outcome. Similar findings have been reported by Butler
and colleagues47 in 182 adult recipients with an average fol-
low-up period of 42  28 months that pretransplant pulmo-
nary hypertension, even when reversible to a PVR of 2.5
WU, is associated with a higher mortality posttransplant. It
is possible that some posttransplant right ventricular charac-
teristics, such as presence of tricuspid regurgitation and
diastolic dysfunction, may develop over time, which may
explain why elevated PVR remains an independent risk
factor for later mortality.
Limitations
This is a retrospective, single-center study and therefore
will be subject to local case mix and practice patterns.
This is of particular relevance when considering the pre-
transplant assessment of PVR and the criteria for transplant
listing, which are known to vary from one center to another.
Certain patient subgroups analyzed are small, and conse-
quently, the reported confidence intervals are wide. The
cohort spans a period of 7 years, over which there were
some practice changes, as familiarity grew with the early
use of iNO and other conventional supportive treatment
for acute RVF after transplant.
CONCLUSIONS
In this pediatric cardiac transplant cohort, acute RVF de-
veloped in one-fourth of recipients—in particular, recipients
with RCM, CHD, and elevated PVR. Despite careful recipi-
ent selection and perioperative care, avoidance of RVF was
not always possible. A protocol for preemptive management
of RVF appears to be critical in high-risk groups. Aggressive
management of RVF with iNO beginning in the operating
room, early prostacyclin therapy, and use of ECMO and
RV afterload reduction are recommended, and we conclude
that this mayminimize early mortality. Further research is re-
quired to reliably identify those pediatric recipients who will
experience transient RVF after heart transplantation. Pre-
transplant elevation of PVR, albeit reactive, remains the sin-
gle most important determinant of long-term outcome.152 The Journal of Thoracic and Cardiovascular SurgWe acknowledge the statistical support provided byMs Deborah
Ridout, MSc, Paediatric Epidemiology & Biostatistics, UCL Insti-
tute of Child Health, 30 Guilford Street, London WC1N 1EH, UK.References
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